536 related articles for article (PubMed ID: 30685685)
1. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S; Bielack SS; Whelan J; Bernstein M; Hogendoorn P; Krailo MD; Gorlick R; Janeway KA; Ingleby FC; Anninga J; Antal I; Arndt C; Brown KLB; Butterfass-Bahloul T; Calaminus G; Capra M; Dhooge C; Eriksson M; Flanagan AM; Friedel G; Gebhardt MC; Gelderblom H; Goldsby R; Grier HE; Grimer R; Hawkins DS; Hecker-Nolting S; Sundby Hall K; Isakoff MS; Jovic G; Kühne T; Kager L; von Kalle T; Kabickova E; Lang S; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Mayer-Steinacker R; Meyers PA; Nagarajan R; Randall RL; Reichardt P; Renard M; Rechnitzer C; Schwartz CL; Strauss S; Teot L; Timmermann B; Sydes MR; Marina N
Eur J Cancer; 2019 Mar; 109():36-50. PubMed ID: 30685685
[TBL] [Abstract][Full Text] [Related]
2. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
Marina NM; Smeland S; Bielack SS; Bernstein M; Jovic G; Krailo MD; Hook JM; Arndt C; van den Berg H; Brennan B; Brichard B; Brown KLB; Butterfass-Bahloul T; Calaminus G; Daldrup-Link HE; Eriksson M; Gebhardt MC; Gelderblom H; Gerss J; Goldsby R; Goorin A; Gorlick R; Grier HE; Hale JP; Hall KS; Hardes J; Hawkins DS; Helmke K; Hogendoorn PCW; Isakoff MS; Janeway KA; Jürgens H; Kager L; Kühne T; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Meyers PA; Mottl H; Nathrath M; Papai Z; Randall RL; Reichardt P; Renard M; Safwat AA; Schwartz CL; Stevens MCG; Strauss SJ; Teot L; Werner M; Sydes MR; Whelan JS
Lancet Oncol; 2016 Oct; 17(10):1396-1408. PubMed ID: 27569442
[TBL] [Abstract][Full Text] [Related]
3. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.
Hauben EI; Weeden S; Pringle J; Van Marck EA; Hogendoorn PC
Eur J Cancer; 2002 Jun; 38(9):1218-25. PubMed ID: 12044509
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS; Smeland S; Whelan JS; Marina N; Jovic G; Hook JM; Krailo MD; Gebhardt M; Pápai Z; Meyer J; Nadel H; Randall RL; Deffenbaugh C; Nagarajan R; Brennan B; Letson GD; Teot LA; Goorin A; Baumhoer D; Kager L; Werner M; Lau CC; Sundby Hall K; Gelderblom H; Meyers P; Gorlick R; Windhager R; Helmke K; Eriksson M; Hoogerbrugge PM; Schomberg P; Tunn PU; Kühne T; Jürgens H; van den Berg H; Böhling T; Picton S; Renard M; Reichardt P; Gerss J; Butterfass-Bahloul T; Morris C; Hogendoorn PC; Seddon B; Calaminus G; Michelagnoli M; Dhooge C; Sydes MR; Bernstein M;
J Clin Oncol; 2015 Jul; 33(20):2279-87. PubMed ID: 26033801
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
6. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
7. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
8. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup.
McTiernan A; Jinks RC; Sydes MR; Uscinska B; Hook JM; van Glabbeke M; Bramwell V; Lewis IJ; Taminiau AH; Nooij MA; Hogendoorn PC; Gelderblom H; Whelan JS
Eur J Cancer; 2012 Mar; 48(5):703-12. PubMed ID: 22036088
[TBL] [Abstract][Full Text] [Related]
9. How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?
Tsoi KM; Lowe M; Tsuda Y; Lex JR; Fujiwara T; Almeer G; Gregory J; Stevenson J; Evans SE; Botchu R; Jeys LM
Clin Orthop Relat Res; 2021 Feb; 479(2):298-308. PubMed ID: 32956141
[TBL] [Abstract][Full Text] [Related]
10. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Piperno-Neumann S; Ray-Coquard I; Occean BV; Laurence V; Cupissol D; Perrin C; Penel N; Bompas E; Rios M; Le Cesne A; Italiano A; Anract P; de Pinieux G; Collard O; Bertucci F; Duffaud F; Le Deley MC; Delaye J; Brugieres L; Blay JY
Int J Cancer; 2020 Jan; 146(2):413-423. PubMed ID: 31246277
[TBL] [Abstract][Full Text] [Related]
11. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Whelan JS; Bielack SS; Marina N; Smeland S; Jovic G; Hook JM; Krailo M; Anninga J; Butterfass-Bahloul T; Böhling T; Calaminus G; Capra M; Deffenbaugh C; Dhooge C; Eriksson M; Flanagan AM; Gelderblom H; Goorin A; Gorlick R; Gosheger G; Grimer RJ; Hall KS; Helmke K; Hogendoorn PC; Jundt G; Kager L; Kuehne T; Lau CC; Letson GD; Meyer J; Meyers PA; Morris C; Mottl H; Nadel H; Nagarajan R; Randall RL; Schomberg P; Schwarz R; Teot LA; Sydes MR; Bernstein M;
Ann Oncol; 2015 Feb; 26(2):407-14. PubMed ID: 25421877
[TBL] [Abstract][Full Text] [Related]
12. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
13. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials.
Whelan JS; Jinks RC; McTiernan A; Sydes MR; Hook JM; Trani L; Uscinska B; Bramwell V; Lewis IJ; Nooij MA; van Glabbeke M; Grimer RJ; Hogendoorn PC; Taminiau AH; Gelderblom H
Ann Oncol; 2012 Jun; 23(6):1607-16. PubMed ID: 22015453
[TBL] [Abstract][Full Text] [Related]
14. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
Lewis IJ; Nooij MA; Whelan J; Sydes MR; Grimer R; Hogendoorn PC; Memon MA; Weeden S; Uscinska BM; van Glabbeke M; Kirkpatrick A; Hauben EI; Craft AW; Taminiau AH; ;
J Natl Cancer Inst; 2007 Jan; 99(2):112-28. PubMed ID: 17227995
[TBL] [Abstract][Full Text] [Related]
15. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
[TBL] [Abstract][Full Text] [Related]
16. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
[TBL] [Abstract][Full Text] [Related]
17. Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt.
Morsy AM; Ahmed BM; Rezk KM; Ramadan IK; Aboelgheit AM; Eltyb HA; Abd Elbadee OM; El-Naggar MS
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e66-e78. PubMed ID: 31107367
[TBL] [Abstract][Full Text] [Related]
18. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
[TBL] [Abstract][Full Text] [Related]
19. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
Tabone MD; Kalifa C; Rodary C; Raquin M; Valteau-Couanet D; Lemerle J
J Clin Oncol; 1994 Dec; 12(12):2614-20. PubMed ID: 7989936
[TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
